Display options
Cite
Coskun Benlidayi I. What are the effects of vasodilators in patients with primary Raynaud's phenomenon? A Cochrane review summary with commentary. Int J Rheum Dis. 2021;doi: 10.1111/1756-185X.14243.
Coskun Benlidayi, I. (2021). What are the effects of vasodilators in patients with primary Raynaud's phenomenon? A Cochrane review summary with commentary. International journal of rheumatic diseases, . https://doi.org/10.1111/1756-185X.14243
Coskun Benlidayi, Ilke. "What are the effects of vasodilators in patients with primary Raynaud's phenomenon? A Cochrane review summary with commentary." International journal of rheumatic diseases vol. (2021). doi: https://doi.org/10.1111/1756-185X.14243
Coskun Benlidayi I. What are the effects of vasodilators in patients with primary Raynaud's phenomenon? A Cochrane review summary with commentary. Int J Rheum Dis. 2021 Nov 29; doi: 10.1111/1756-185X.14243. Epub 2021 Nov 29. PMID: 34845840.
Copy Download .nbib Format: NLM
Share it on

Int J Rheum Dis. 2021 Nov 29; doi: 10.1111/1756-185X.14243. Epub 2021 Nov 29.

What are the effects of vasodilators in patients with primary Raynaud's phenomenon? A Cochrane review summary with commentary.

International journal of rheumatic diseases

Ilke Coskun Benlidayi

Affiliations

  1. Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Cukurova University, Adana, Turkey.

PMID: 34845840 DOI: 10.1111/1756-185X.14243

[No abstract available.]

Keywords: Cochrane review summary; Raynaud’s phenomenon; therapeutics; vasodilator agents; vasodilators

References

  1. Su KY, Sharma M, Kim HJ, et al. Vasodilators for primary Raynaud's phenomenon. Cochrane Database Syst Rev. 2021;2021(5):CD006687. - PubMed
  2. Maverakis E, Patel F, Kronenberg DG, et al. International consensus criteria for the diagnosis of Raynaud's phenomenon. J Autoimmun. 2014;48-49:60-65. - PubMed
  3. Herrick AL. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. Nat Rev Rheumatol. 2012;8(8):469-479. 10.1038/nrrheum.2012.96 - PubMed
  4. Hughes M, Herrick AL. Raynaud's phenomenon. Best Pract Res Clin Rheumatol. 2016;30(1):112-132. 10.1016/j.berh.2016.04.001 - PubMed
  5. Wigley FM, Flavahan NA. Raynaud's Phenomenon. N Engl J Med. 2016;375(6):556-565. 10.1056/NEJMra1507638 - PubMed
  6. Stewart M, Morling JR. Oral vasodilators for primary Raynaud's phenomenon. Cochrane Database Syst Rev. 2012;7:CD006687. 10.1002/14651858.CD006687.pub3 - PubMed
  7. Garner R, Kumari R, Lanyon P, Doherty M, Zhang W. Prevalence, risk factors and associations of primary Raynaud's phenomenon: systematic review and meta-analysis of observational studies. BMJ Open. 2015;5(3):e006389. 10.1136/bmjopen-2014-006389 - PubMed
  8. De Angelis R, Salaffi F, Grassi W. Health-related quality of life in primary raynaud phenomenon. J Clin Rheumatol. 2008;14(4):206-210. 10.1097/RHU.0b013e31817a2485 - PubMed
  9. Hughes M, Snapir A, Wilkinson J, Snapir D, Wigley FM, Herrick AL. Prediction and impact of attacks of Raynaud’s phenomenon, as judged by patient perception. Rheumatology. 2015;54(8):1443-1447. 10.1093/rheumatology/kev002 - PubMed
  10. Pope JE. Raynaud's phenomenon (primary). BMJ Clin Evid. 2011;2011:1119. - PubMed
  11. World Health Organization. The International Classification of Functioning, Disability and Health (ICF). WHO; 2001. - PubMed
  12. Fábián B, Fábián AK, Bugán A, Csiki Z. Comparison of mental and physical health between patients with primary and secondary Raynaud's phenomenon. J Psychosom Res. 2019;116:6-9. 10.1016/j.jpsychores.2018.11.001 - PubMed

Publication Types